VRDN - NASDAQ

Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc.

VRDNยทNASDAQ

$16.92

+6.6%
HealthcareBiotechnology

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$1.52B
EPS-3.3200
P/E Ratio-5.10
Earnings Date08/05/2026
Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc. Fair Value Envelope

VRDN ยท NASDAQ

Our analysis suggests that VRDN has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $16.9196, this represents a potential HIDDEN relative to our calculated worth for Viridian Therapeutics, Inc..

HIDDEN
Intrinsic Value
Current Price: $16.9196

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$785.3M
+ Cash & Equivalents$212.4M
Firm Value-$572.9M
- Debt$50.7M
Equity Value-$623.6M
/ Shares Outstanding81,180,045B
DCF Value-$8
OVERVALUED BY 145%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$224.1M
-$181.7M
-$147.3M
-$119.4M
-$96.8M
-$78.5M
-$63.7M
-$51.6M
-$41.8M
-$33.9M
Maintenance CapEx
-$80.3K
-$65.1K
-$52.8K
-$42.8K
-$34.7K
-$28.1K
-$22.8K
-$18.5K
-$15.0K
-$12.2K
Owner Earnings
-$224.2M
-$181.8M
-$147.4M
-$119.5M
-$96.9M
-$78.5M
-$63.7M
-$51.6M
-$41.9M
-$33.9M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$207.6M
-$155.8M
-$117.0M
-$87.8M
-$65.9M
-$49.5M
-$37.2M
-$27.9M
-$20.9M
-$15.7M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your VRDN research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.